Its first-in-human phase Ia trial in pretreated solid tumors with PIK3CA mutations showed its tolerability and efficacy in several types of PIK3CA-mutant solid tumors such as breast, ovarian, and gastric cancers [134]. This evidence concerns the gene PIK3CA and gastric cancer.